著者

中島 康夫 山崎 真樹子 鈴木 清一 井上 嘉則 上茶谷 若 山本 敦

出版者

公益社団法人 日本分析化学会

雑誌

分析化学 = Japan analyst (ISSN:05251931)

巻号頁・発行日

vol.62, no.4, pp.349-354, 2013-04-05

参考文献数

30

被引用文献数

1

---

イオン性化合物分析における金属酸化物系吸着剤の選択的抽出剤としての適用性を調べるため,グリホサート[<i>N</i>-(phosphonomethyl)glycine, GLYP]を測定対象としてジルコニア及びチタニアの抽出・溶出特性を調べた.ジルコニア及びチタニアともリン酸化合物に対して高い親和性を示すとされているが,本検討で用いたチタニアからはGLYPの漏出が観察された.一方,ジルコニアはGLYPを明確に保持し,試料溶液を250 mL負荷しても良好に捕捉することができた.ジルコニアに捕集されたGLYPは0.4 M水酸化ナトリウム2 mLで定量的に溶出できた.この溶出液を,サプレッサモジュールを用いて中和させることで,電気伝導度検出─イオンクロマトグラフィーでGLYPを高感度検出することが可能であった.本法を都市型河川水に適用したところ,1 &mu;g L^-1程度のGLYPを定量することができた.

著者

犬山 征夫 浅岡 一之 中島 康夫 甲能 直幸 小津 雷助 増野 精二 堀内 正敏

出版者

耳鼻咽喉科臨床学会

雑誌

耳鼻咽喉科臨床 (ISSN:00326313)

巻号頁・発行日

vol.72, no.12, pp.1613-1620, 1979-12-01 (Released:2011-11-04)

参考文献数

15

被引用文献数

1

---

We gave OK-432, a preparation made from a low virulent strain of streptococcus hemolyticus, to 68 patients with head and neck cancer by intramuscular injection and 2 patients were treated with local application. Anatomical site of the tumor in 70 cases was as follows; nose and paranasal sinus 22, nasopharynx 17, base of oral cavity and tongue 14, mesopharynx 8, larynx 6 and miscellaneous 3. We administered OK-432 mainly as an adjuvant immunotherapy after radical surgery or radiotherapy. The daily dose of OK-432 was 0.2KE, then the dose was gradually augmented and the maintenance dose was 3-5KE. The longest duration of OK-432 administration was 3 years and 6 months. We evaluated OK-432 from the point of view of the immunological parameters and the recurrence rate. Complement level (CH50) and tuberculin reactivity were measured as possible indices of the humoral and cell-mediated immune status. “The six stage classification after CH50 and tuberculin reaction” as suggested by Nishioka was employed and an analysis carried out.The results obtained were as follows:1. OK-432 had no tumor-reducing effects in advanced or recurrent cases.2. Immunological findings suggested that OK-432 had prophylactic effects against recurrence and metastasis.3. The recurrence rate of OK-432-treated group was almost the same as that in the control group, however, the recurrence rate of OK-432 and FT-207 treated groups was 26%, this rate being considerably lower than that in the control group. We concluded that adjuvant chemo-immunotherapy was more effective than adjuvant immunotherapy alone for prevention of recurrence and metastasis.